Table 1 Baseline characteristics of study participants
Life-threatening COVID-19 | Infected controls | P valuea | |
|---|---|---|---|
n = 3269 | n = 1373 | ||
Sex, no. (%) | < 0.0001 | ||
Male | 2314 (70.8%) | 542 (39.5%) | |
Female | 955 (29.2%) | 831 (60.5%) | |
Age (years) | |||
Mean (SD) | 55.74 (17.40) | 43.83 (20.14) | < 0.0001 |
Median (range) | 57 (0.08–99) | 43 (0.08–105) | |
Processing pipeline, no. (%) | < 0.0001 | ||
HGID laboratory | 2492 (76.2%) | 870 (63.4%) | |
Other | 777 (24.8%) | 503 (36.6%) | |
Ancestry, no. (%) | < 0.0001 | ||
European | 1374 (42.0%) | 960 (69.9%) | |
Middle Eastern | 483 (14.8%) | 158 (11.5%) | |
Admixed American | 466 (14.3%) | 109 (7.9%) | |
North African | 300 (9.2%) | 24 (1.7%) | |
South Asian | 279 (8.5%) | 36 (2.6%) | |
Sub-Saharan African | 234 (7.1%) | 43 (3.1%) | |
East Asian | 133 (4.1%) | 43 (3.1%) | |